LONDON: The biotech startup behind the Covid-19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S.
regulators for a public share offering.Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.
The Wall Street Journal reported Wednesday that the IPO filing could come as soon as this week. The U.K.-based company plans to list on New York’s Nasdaq with the ticker symbol VACC.The company was started by two Oxford scientists who helped lead the Covid-19 vaccine development and who spun Vaccitech out of the university in 2016, with the goal of turning laboratory discoveries.